Windsor-Essex COVID-19 Antibody Survey Initiative
Standing
Undergraduate
Type of Proposal
Oral Research Presentation
Faculty
Faculty of Science
Faculty Sponsor
none.
Proposal
In the wake of the SARS-CoV-2 (COVID-19) pandemic, it has become clear that it is important to develop and implement COVID-19 detection methods that are quick and simple-to-use. While PCR tests are accurate and produce results on a relatively short time scale, there is room for improvement and Audacia Bioscience is seeking to develop an improved detection methodology.
The CMC-19D SARS-CoV-2 Rapid Antibody Test is a point-of-care rapid in-vitro diagnostic test using lateral flow technology for detection of the IgM-IgG SARS-CoV-2 antibodies. The test will identify qualitative detection of IgM and IgG antibodies of SARS-CoV-2 in whole blood, serum or plasma (EDTA) from individuals suspected of recent or past exposure with results being available in 10-15 minutes. Recombinant Covid-19 nucleoprotein antigen is used in the test. Covid-19 antibodies in the specimen will bind to gold-conjugated Covid-19 nucleoprotein antigens forming antibody – colloid gold-antigen complex. While the complex migrates along the nitrocellulose membrane, the complex is captured on the test lines coated with anti-human IgM or IgG causing a pink to deep pink band at the IgG or IgM test line.
This study evaluated participants across multiple locations, including Erie Shores, Windsor Regional Hospital, and other local pharmacies to determine the accuracy of the Rapid Antibody Test. Our results were unfortunately not derived from a large enough sample size to make valid conclusions, however, we are in the process of adding more data to provide a clearer picture on the functionality of the rapid antibody testing kit.
Availability
March 29, March 30, March 31, and April 1, 12-3pm.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Special Considerations
Presenters: Mustafa Abumeeiz and Lauren Elliott
Additional Information: My co-presenter and I are both one year alumni. We are hoping to be able to participate as we wanted to participate in our last year (2020) of undergraduate studies, however, the conference was cancelled due to the COVID-19 pandemic.
Windsor-Essex COVID-19 Antibody Survey Initiative
In the wake of the SARS-CoV-2 (COVID-19) pandemic, it has become clear that it is important to develop and implement COVID-19 detection methods that are quick and simple-to-use. While PCR tests are accurate and produce results on a relatively short time scale, there is room for improvement and Audacia Bioscience is seeking to develop an improved detection methodology.
The CMC-19D SARS-CoV-2 Rapid Antibody Test is a point-of-care rapid in-vitro diagnostic test using lateral flow technology for detection of the IgM-IgG SARS-CoV-2 antibodies. The test will identify qualitative detection of IgM and IgG antibodies of SARS-CoV-2 in whole blood, serum or plasma (EDTA) from individuals suspected of recent or past exposure with results being available in 10-15 minutes. Recombinant Covid-19 nucleoprotein antigen is used in the test. Covid-19 antibodies in the specimen will bind to gold-conjugated Covid-19 nucleoprotein antigens forming antibody – colloid gold-antigen complex. While the complex migrates along the nitrocellulose membrane, the complex is captured on the test lines coated with anti-human IgM or IgG causing a pink to deep pink band at the IgG or IgM test line.
This study evaluated participants across multiple locations, including Erie Shores, Windsor Regional Hospital, and other local pharmacies to determine the accuracy of the Rapid Antibody Test. Our results were unfortunately not derived from a large enough sample size to make valid conclusions, however, we are in the process of adding more data to provide a clearer picture on the functionality of the rapid antibody testing kit.